Sat.Jan 11, 2025 - Fri.Jan 17, 2025

article thumbnail

Is ‘Big Data’ the Cure-all for U.S. Healthcare?

MedCity News

AI/big data haven’t solved healthcare’s challenges. Despite advancements, systemic barriers persist, but AI offers potential to improve outcomes and efficiency. The post Is Big Data the Cure-all for U.S. Healthcare? appeared first on MedCity News.

article thumbnail

CDC wants faster testing for bird flu in hospitals

pharmaphorum

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu, says CDC.

120
120
article thumbnail

Merck is broadening its pipeline as Keytruda’s patent cliff looms

PharmaVoice

Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

116
116
article thumbnail

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

Pharmaceutical Technology

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

MedCity News

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings appeared first on MedCity News.

article thumbnail

Pheno Therapeutics granted trial authorisation for MS candidate

PharmaTimes

First-in-human trial of PTD802 to commence following UK MHRA approval

109
109

More Trending

article thumbnail

Shionogi awarded $375m from HHS for preventative Covid-19 injectable

Pharmaceutical Technology

Shionogis S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao via Getty Images.

105
105
article thumbnail

Precision Medicine: Becoming More Real With AI?

MedCity News

With technology advancements specifically in the field of AI, there is a clear line of sight in making it mainstream. Here are some of the ways AI is helping to accelerate the adoption of PM. The post Precision Medicine: Becoming More Real With AI? appeared first on MedCity News.

Medicine 138
article thumbnail

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

PharmaTimes

New partnership to advance precision medicine in lung cancer diagnosis

Medicine 106
article thumbnail

Keros pulls study of Winrevair rival after safety signal

pharmaphorum

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair

Safety 106
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Lilly gains US FDA approval for Omvoh to treat Crohn’s disease

Pharmaceutical Technology

Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult population.

FDA 105
article thumbnail

Form Health Unveils New Program to Prevent the Transition from Overweight to Obesity

MedCity News

Form Health launched a new program for people who are overweight that includes meetings with a registered dietitian and a personalized care plan. The post Form Health Unveils New Program to Prevent the Transition from Overweight to Obesity appeared first on MedCity News.

120
120
article thumbnail

AI set to revolutionise pharmaceutical R&D says GlobalData

PharmaTimes

Survey finds AI to enhance productivity and cut costs in the next 12 months

article thumbnail

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

pharmaphorum

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth

FDA 104
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast

Pharmaceutical Technology

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

FDA 105
article thumbnail

At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected

MedCity News

Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue. The post At JPM, Eli Lillys CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected appeared first on MedCity News.

Sales 113
article thumbnail

Owlstone Medical announces $27 million USD first close in Series E financing round

PharmaTimes

Funds to accelerate commercialisation and clinical trials of diagnostic tests

Medical 107
article thumbnail

What to expect in the sequel to Medicare’s drug price negotiation program

PharmaVoice

CMS is expected to publish up to 15 drugs for the second cycle of the program by Feb. 1, and these are some of the drugs most likely to make the list.

104
104
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure

Pharmaceutical Technology

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients.

105
105
article thumbnail

A Checklist to Help Healthcare Practices Thrive

MedCity News

A new report from Relatient highlights ways hospitals and physician practices can improve workflows and how to create frictionless patient interactions. The post A Checklist to Help Healthcare Practices Thrive appeared first on MedCity News.

article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

PharmaTimes

Companies aim to provide new treatments for inflammatory conditions

Pharma 108
article thumbnail

GSK confirms plan to buy cancer firm IDRx for $1bn

pharmaphorum

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103
103
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma to raise prices on more than 250 drugs in the US from January 2025

Pharmaceutical Technology

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

Pharma 105
article thumbnail

J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

MedCity News

Johnson & Johnsons agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared first on MedCity News.

article thumbnail

Oxford Drug Design achieves in vivo validation for novel cancer treatment

PharmaTimes

Promising results from mouse study lead to expanded trials

Leads 107
article thumbnail

FDA bans red dye used in medicines over cancer risk

pharmaphorum

The FDA has banned the use of a red dye used in oral medicines, foods, and dietary supplements, more than 30 years after it was linked to cancer.

article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

article thumbnail

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Pharmaceutical Technology

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

98
article thumbnail

Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation?

MedCity News

More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though it got approved later, reimbursement has been elusive. All that might change this year. The post Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation? appeared first on MedCity News.

113
113
article thumbnail

Actinogen boosts trial with Cambridge Cognition’s digital suite

PharmaTimes

Partnership aims to advance Alzheimer's research with innovative tools

91
article thumbnail

Boehringer drug for brain fog in schizophrenia fails trial

pharmaphorum

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

98
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten